CN1301729C - 一种治疗强直性脊柱炎的药物及其制备方法 - Google Patents
一种治疗强直性脊柱炎的药物及其制备方法 Download PDFInfo
- Publication number
- CN1301729C CN1301729C CNB2003101017181A CN200310101718A CN1301729C CN 1301729 C CN1301729 C CN 1301729C CN B2003101017181 A CNB2003101017181 A CN B2003101017181A CN 200310101718 A CN200310101718 A CN 200310101718A CN 1301729 C CN1301729 C CN 1301729C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- ankylosing spondylitis
- parts
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 229940079593 drug Drugs 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 15
- 230000008569 process Effects 0.000 title description 3
- 208000007442 rickets Diseases 0.000 title 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims abstract description 43
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 241000218176 Corydalis Species 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 9
- 241000219780 Pueraria Species 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 5
- 241000903946 Clematidis Species 0.000 claims description 3
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 3
- 244000113306 Monascus purpureus Species 0.000 claims description 3
- 229940057059 monascus purpureus Drugs 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 abstract description 8
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 abstract description 8
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 abstract description 8
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 abstract description 8
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 abstract description 8
- 229940074393 chlorogenic acid Drugs 0.000 abstract description 8
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 abstract description 8
- 235000001368 chlorogenic acid Nutrition 0.000 abstract description 8
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 abstract description 8
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 abstract description 6
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 abstract description 6
- 229940039750 aconitine Drugs 0.000 abstract description 6
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 abstract description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 abstract description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 abstract description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 abstract 2
- AEQDJSLRWYMAQI-QGZVFWFLSA-N (13ar)-2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5h-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-QGZVFWFLSA-N 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 229960003720 enoxolone Drugs 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 238000012360 testing method Methods 0.000 description 31
- 239000013558 reference substance Substances 0.000 description 20
- 238000000605 extraction Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000000988 bone and bone Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N Tetrahydropalmatine Natural products C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- SQMGCPHFHQGPIF-UUKFDUHUSA-N gns9eex31x Chemical compound O[C@@H]([C@]([C@H]([C@H](O)[C@]12O)OC)(O)C3)[C@H]2[C@@H]3[C@@]2([C@H](C[C@H]3O)OC)[C@H]4[C@@H]1[C@H](OC)[C@@H]2[C@]3(COC)CN4CC SQMGCPHFHQGPIF-UUKFDUHUSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- -1 reflux Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000003131 sacroiliac joint Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
因素水平 | A醇浓度 | B溶媒量(倍) | C提取时间(小时) | D提取次数 |
123 | 65%75%85% | 468 | 123 | 123 |
列号因素 | 1A醇浓度 | 2B溶媒量(倍) | 3C提取时间(小时) | 4D提取次数 | 总生物碱量(mg) |
123456789 | 111222333 | 123123123 | 123231312 | 123312231 | 12.2638.0625.8036.1216.7727.7422.5816.7718.70 |
K1K2K3 | 76.1280.6358.05 | 70.9671.6072.24 | 56.7792.8865.15 | 47.7388.3878.69 | G=214.80 |
K1K2K3 | 25.3726.8819.35 | 23.6523.8724.08 | 18.9230.9621.72 | 15.9129.4626.23 | |
R | 7.53 | 0.43 | 12.04 | 13.55 |
方差来源 | 平方和 | 自由度 | 均方 | F值 | 因素影响 |
醇浓度(A)溶媒量(B)提取时间(C)提取次数(D) | 95.190.27238.12300.54 | 2222 | 47.600.135119.06150.27 | 3528821113 | 高度显著高度显著高度显著 |
总和 | 634.12 | 8 |
测量值 | 基线值 | 0-6个月 | ||
平均值 | 差别百分数 | P | ||
Bath强直性脊柱炎病情活动指数Bath强直性脊柱炎功能指数晨僵时间 | 26.2023.8050min | -6.75-5.28-20 | 25.7622.1840.00 | <0.05<0.05<0.01 |
观察项目 | 指地距(cm) | 枕壁试验(cm) | 扩胸度(cm) | Schobe试验(cm) |
治疗前治疗后 | 7.53±2.675.25±1.13* | 4.20±2.711.32±1.75* | 2.15±1.822.25±1.20 | 2.43±1.624.54±2.13* |
测量值 | 基线值 | 0-6个月 | ||
平均值 | 差别百分数 | P | ||
血沉C反应蛋白 | 40.235.70 | -5.49-2.54 | 13.6444.56 | <0.05<0.05 |
观察项目 | 白细胞(×109/L) | 红细胞(×1012/L) | 血红蛋白(g/L) | 血小板(×109/L) | 丙氨酸氨基转移酶(IU/L) | 门冬氨酸氨基转移酶(IU/L) | 尿素氮(mol/L) | 肌酐(umol/L) |
治疗前治疗后 | 5.5±1.24.9±1.1 | 3.5±0.83.8±0.6 | 110±15125±12 | 180±98167±112 | 21±1218±11 | 13±1115±12 | 5.6±2.16.2±1.3 | 79±2566±28 |
观察项目 | 白细胞 | 红细胞 | 蛋白 |
治疗前治疗后 | ———— | ———— | ———— |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101017181A CN1301729C (zh) | 2003-10-21 | 2003-10-21 | 一种治疗强直性脊柱炎的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101017181A CN1301729C (zh) | 2003-10-21 | 2003-10-21 | 一种治疗强直性脊柱炎的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1608634A CN1608634A (zh) | 2005-04-27 |
CN1301729C true CN1301729C (zh) | 2007-02-28 |
Family
ID=34756234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101017181A Expired - Lifetime CN1301729C (zh) | 2003-10-21 | 2003-10-21 | 一种治疗强直性脊柱炎的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1301729C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108392488A (zh) * | 2018-05-29 | 2018-08-14 | 刘娟 | 芍药苷在制备ido抑制剂中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1311027A (zh) * | 2001-02-26 | 2001-09-05 | 王希贵 | 一种治疗类风湿关节炎、骨性关节炎和强直性脊柱炎的药物 |
CN1335147A (zh) * | 2000-07-26 | 2002-02-13 | 郭豪 | 用于治疗强直性脊柱炎的纯中药散剂 |
CN1411829A (zh) * | 2001-10-17 | 2003-04-23 | 宋大文 | 治疗脊柱增生性关节炎的药及其制备方法 |
-
2003
- 2003-10-21 CN CNB2003101017181A patent/CN1301729C/zh not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1335147A (zh) * | 2000-07-26 | 2002-02-13 | 郭豪 | 用于治疗强直性脊柱炎的纯中药散剂 |
CN1311027A (zh) * | 2001-02-26 | 2001-09-05 | 王希贵 | 一种治疗类风湿关节炎、骨性关节炎和强直性脊柱炎的药物 |
CN1411829A (zh) * | 2001-10-17 | 2003-04-23 | 宋大文 | 治疗脊柱增生性关节炎的药及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1608634A (zh) | 2005-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1768854B (zh) | 一种用于溃疡性结肠炎的中药胶囊制剂 | |
CN101991785B (zh) | 一种银翘解毒软胶囊药物及其制备方法与质量检测方法 | |
CN101254284B (zh) | 一种治疗风湿病的药物组合物及制备方法和检测方法 | |
CN104288245B (zh) | 抗衰老和增强体质的药物组合物及其制备方法和检测方法 | |
CN1332710C (zh) | 一种补肾的药物组合物及其制备方法和新用途 | |
CN101485872B (zh) | 一种治疗胃病的中药组合物及其制备和检测方法 | |
CN100571761C (zh) | 一种治疗肝病的中药组合物及制备方法 | |
CN102885928B (zh) | 一种治疗黄疸的中药注射剂及其制备方法 | |
CN104173950A (zh) | 一种治疗前列腺癌的中草药组合物 | |
CN111375035B (zh) | 一种治疗颈椎病的肠溶制剂的制备及应用 | |
CN104606494A (zh) | 一种用于治疗肝癌的中药及其制备方法 | |
CN106074810A (zh) | 一种三妙胶囊及其制备方法 | |
CN1301729C (zh) | 一种治疗强直性脊柱炎的药物及其制备方法 | |
CN104189781A (zh) | 一种治疗神经胶质瘤的中药组合物 | |
CN106853021A (zh) | 防治慢性肾脏病的中药组合物及其制备方法和应用 | |
CN106266343A (zh) | 一种脑血疏的制备方法 | |
CN1148217C (zh) | 治疗慢性支气管炎的中成药 | |
CN101264188B (zh) | 一种治疗风湿性关节炎的口服药酒及其制备方法 | |
CN1903314A (zh) | 治疗头痛,失眠,心悸,乏力的中药组合物及其制备方法 | |
CN102233084B (zh) | 一种用于治疗前列腺炎的中药组合物及其制备方法 | |
CN1272047C (zh) | 一种补益肝肾治疗肠燥便秘的药物 | |
CN1927309B (zh) | 一种中药组合物的检测方法 | |
CN104873909B (zh) | 治疗无症状非转移性去势抵抗性前列腺癌的中草药组合物 | |
CN103768305A (zh) | 一种治疗脾虚腹泻型肠易激综合症的药物及其制造方法 | |
CN103800736A (zh) | 一种治疗高血压肾病的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: GENERAL HOSPITAL OF CHINESE PLA Effective date: 20110322 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100853 NO. 28, FUXING ROAD, BEIJING TO: 300410 NO. 2, PUJIHE EAST ROAD, BEICHEN DISTRICT, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110322 Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 Patentee after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: 100853, Fuxing Road, Beijing, No. 28 Patentee before: CHINESE PLA GENERAL Hospital |
|
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070228 |